Palantir Technologies lifts guidance after Q2 results beat Wall Street estimates
Aditx Therapeutics, Inc. (ADTX) stock has reached a new 52-week low, touching the $4 mark, with a market capitalization now at just $1.2 million. InvestingPro analysis shows the stock is currently in oversold territory, though investors should note the company's concerning financial metrics. Over the past year, the biotech firm, which focuses on improving the health of the immune system through its technologies, has seen its stock price plummet, culminating in a staggering 1-year change of nearly -99.99%. This precipitous drop reflects investor concerns, supported by InvestingPro data showing a concerning current ratio of 0.09 and negative gross margins. As Aditx Therapeutics continues to navigate through these turbulent times, stakeholders are closely monitoring its strategies for recovery and future growth, with 12 additional key metrics available on InvestingPro to help assess the company's trajectory.
In other recent news, Aditxt, Inc. has amended its merger agreement with Evofem Biosciences (OTC:EVFM), extending the completion deadline to September 30, 2025, and committing an additional $1.5 million investment. This merger, which has undergone several amendments, is subject to shareholder approval, with a vote expected by September 26, 2025. Meanwhile, Aditxt is advancing clinical trials for its autoimmune therapy, ADI-100, with regulatory submissions underway in both the U.S. and Germany. The company's subsidiary, Pearsanta, is progressing towards a commercial launch of blood-based tests for Prostate Cancer and Endometriosis, with plans for an IPO. Additionally, Aditxt has announced a 1-for-250 reverse stock split to meet Nasdaq's minimum bid price requirement, effective March 17, 2025. This decision follows a shareholder vote approving the reverse stock split. Aditxt has also extended its acquisition agreement with Appili Therapeutics and is in discussions with Evofem Biosciences regarding strategic integration. These developments reflect Aditxt's ongoing efforts to advance its subsidiaries and execute strategic acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.